{"id":4455,"date":"2025-09-09T13:40:50","date_gmt":"2025-09-09T10:40:50","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4455"},"modified":"2025-09-09T13:43:30","modified_gmt":"2025-09-09T10:43:30","slug":"solid-biosciences-sgt-003-gene-therapy-phase-3-clinical-trial-nct07160634","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/solid-biosciences-sgt-003-gene-therapy-phase-3-clinical-trial-nct07160634\/","title":{"rendered":"Solid Biosciences inicia el ensayo cl\u00ednico de fase 3 de la terapia g\u00e9nica SGT-003 (IMPACT DUCHENNE) en varones ambulantes"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Se espera que el estudio de fase 3 (NCT07160634) de la terapia g\u00e9nica SGT-003 desarrollada por Solid Biosciences comience en octubre de 2025 y finalice en enero de 2029.<\/strong> El estudio de fase 3 del SGT-003 incluir\u00e1 a 80 hombres ambulatorios, adem\u00e1s a\u00fan no se han compartido las ubicaciones del estudio. <strong>Leer m\u00e1s<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/es\/faq-solid-biosciences-sgt-003-gene-therapy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Preguntas frecuentes sobre la terapia g\u00e9nica Solid Biosciences SGT-003<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Estudio de fase 3 de terapia g\u00e9nica SGT-003 \u2013 NCT07160634 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Este es un estudio de fase 3, doble ciego, controlado con placebo, cuyo objetivo principal es evaluar la eficacia de una infusi\u00f3n intravenosa \u00fanica de SGT-003 en participantes varones pedi\u00e1tricos ambulatorios con DMD. Los objetivos secundarios incluyen la evaluaci\u00f3n de resultados adicionales de eficacia y seguridad.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Inicio del estudio (estimado)<\/strong>: 2025-10<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Finalizaci\u00f3n primaria (estimada)<\/strong>: 2029-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Finalizaci\u00f3n del estudio (estimada)<\/strong>: 2034-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00famero de participantes (estimado)<\/strong>: 80<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tipo de estudio<\/strong>:Intervencionista<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ubicaciones<\/strong>:A\u00fan no hay datos de ubicaci\u00f3n.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Edades elegibles para estudiar<\/strong>: 7 a 11 a\u00f1os (varones ambulantes)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Criterios principales de inclusi\u00f3n y exclusi\u00f3n. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07160634\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07160634<\/a> \u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">C\u00f3mo participar en el ensayo cl\u00ednico SGT-003<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Para participar en el ensayo cl\u00ednico de fase 3 SGT-003, puede utilizar la informaci\u00f3n de contacto que aparece a continuaci\u00f3n.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nombre<\/strong>:Solid Biosciences<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00famero de tel\u00e9fono<\/strong>: 6173374680<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Correo electr\u00f3nico<\/strong>: ensayos cl\u00ednicos@solidbio.com<\/p>","protected":false},"excerpt":{"rendered":"<p>The phase 3 study (NCT07160634) of the SGT-003 gene therapy developed by Solid Biosciences is expected to begin in October 2025 and be completed in January 2029. The SGT-003 Phase 3 study will include 80 ambulant males, moreover the study locations have not yet been shared. Read More: Frequently Asked Questions About Solid Biosciences SGT-003 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4459,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[137,242,61,419,110,170,109],"class_list":["post-4455","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trial","tag-clinical-trials","tag-gene-therapy","tag-impact-duchenne","tag-sgt-003","tag-sgt-003-gene-therapy","tag-solid-biosciences"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=4455"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4455\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/4459"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=4455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=4455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=4455"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}